Aims and objectives of this session
The course of bladder cancer could be affected by many factors. In order to predict the course of the disease, it is important to analyze multiple parameters. Studies presented in this session will focus also on exosomes and miRNA.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*519 Tumor-associated exosomes of urothelial bladder cancer cells affect tumor-promoting processes in normal bladder fibroblasts and support tumorigenesis
By: Baumgart S.1, Heinzelmann J.1, Krause E.2, Stöckle M.1, Stampe Ostenfeld M.3, Junker K.1
Institutes: 1 Saarland University Medical Center, Dept. of Urology, Homburg, Germany, 2 Saarland University Medical Center, Dept. of Physiology, Homburg, Germany, 3 University Hospital Aarhus, Dept. of Molecular Medicine, Aarhus, Denmark

520 Cancer-associated fibroblasts secreted exosomal miR-146a promotes bladder cancer progression
By: Zhuang J.1, Shen L.2, Yan J.2, Guo H.1
Institutes: 1 Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China, 2 MOE Key Laboratory of Model Animals For Disease Study, Model Animal Research Center, Dept. of Tumor Biology, Nanjing, China

521 Genomic landscape of upper urinary tract urothelial carcinoma
By: Fujii Y.1, Sato Y.1, Suzuki H.2, Shiozawa Y.2, Yoshizato T.2, Yoshida K.2, Shiraishi Y.2, Nakagawa T.1, Kume H.1, Nishimatsu H.2, Okaneya T.5, Sanada M.6, Makishima H.2, Miyano S.3, Ogawa S.2, Homma Y.1
Institutes: 1 The University Of Tokyo Hospital, Dept. of Urology, Bunkyo, Japan, 2 Graduate School of Medicine Kyoto University, Dept. of Pathology and Tumor Biology, Kyoto, Japan, 3 Institute of Medical Science The University of Tokyo, Laboratory of DNA Information Analysis, Human Genome Center, Minato, Japan, 4 The Fraternity Memorial Hospital, Dept. of Urology, Sumida, Japan, 5 Toranomon Hospital, Dept. of Urology, Minato, Japan, 6 Nagoya Medical Center, Advanced Diagnosis, Clinical Research Center, Nagoya, Japan

*522 Molecular subtype classification of advanced bladder cancer and matched lymph-node metastases by integrative immunohistochemistry, gene expression, and mutation analyses
By: Sjödahl G.1, Eriksson P.5, Lövgren K.2, Liedberg F.1, Höglund M.2
Institutes: 1 Translational Medicine, Dept. of Urologic Research, Lund, Sweden, 2 Clinical Sciences, Dept. of Oncology and Pathology, Lund, Sweden

523 Withdrawn
By: Institutes:

524 Urine based DNA methylation biomarkers for monitoring bladder cancer
By: Van Der Heijden A.2, Mengual L.1, Ingelmo-Torres M.1, Lozano J.3, Van Rijt-Van De Westerlo C.4,
Utilization of next-generation sequencing techniques to investigate markers for chemosensitivity in bladder cancer patients treated with neoadjuvant chemotherapy prior to radical cystectomy

By: Bostöm P.¹, Fey V.², Kaikkonen E.³, Lamminen T.¹, Laitinen A.¹, Mirtti T.⁴, Koskinen I.⁵, Salminen A.¹, Taimen P.⁶, Schleutker J.³

Institutes:¹Turku University Hospital, Dept. of Urology, Turku, Finland, ²University of Turku, Institute of Biotechnology, Turku, Finland, ³Turku University, Dept. of Medical Biochemistry and Genetics, Turku, Finland, ⁴Helsinki University Hospital and Finnish Institute For Molecular Medicine, University of Helsinki, Dept. of Pathology (HUSLAB), Helsinki, Finland, ⁵Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ⁶Turku University Hospital, Dept. of Pathology, Turku, Finland

Bladder cancer-secreted extracellular vesicles destroy vascular endothelial barriers

By: Yoneyama M.S.¹, Hatakeyama S.², Funyu T.³, Tsuboi S.¹, Ohyama C.²

Institutes:¹Oyokyo Kidney Research Institute, Dept. of Cancer Immunology and Cell Biology, Hiroaki, Japan, ²Hiroaki University Graduate School of Medicine, Dept. of Urology, Hiroaki, Japan, ³Oyokyo Kidney Research Institute, Dept. of Urology, Hiroaki, Japan

KRT5 and KRT20 expression predicts recurrence and progression of stage pT1 non-muscle-invasive bladder cancer (NMIBC)

By: Breyer J.¹, Wirtz R.², Denzinger S.¹, Erben P.³, Kriemgim M.³, Stoehr R.⁴, Eckstein M.⁴, Burger M.⁵, Otto W.¹, Hartmann A.³

Institutes:¹University of Regensburg, Dept. of Urology, Regensburg, Germany, ²Stratifyer Molecular Pathology GmbH, Cologne, Germany, ³University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, ⁴University of Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany

Cell-free DNA from urine samples – a valuable source for bladder cancer biomarkers?

By: Salomo K., Moritz S., Füssel S., Wirth M.

Institutes:Universitätsklinikum Carl Gustav Carus, Dept. of Urology, Dresden Johannstadt Nord, Germany

SMYD3 drives IGF-1R-AKT pathway activation in bladder cancer

By: Liu L.¹, Fan Y.², Wang K.², Yan K.², Liu C.²

Institutes:¹Shandong University, School of Nursing, Jinan, China, ²Shandong University Qilu Hospital, Dept. of Urology, Jinan, China

Her2 alterations in muscle-invasive bladder cancer: There is more than protein expression in patient selection for targeted therapy

By: Kiss B.², Wyatt A.³, Douglas J.⁴, Skuginna V.², Mo F.², Anderson S.², Rotzer D.², Fleischmann A.³, Genitsch V.¹, Hayashi T.⁶, Neuenschwander M.⁶, Bürki C.⁷, Davicenzi E.⁷, Collins C.³, Thalmann G.², Black P.², Seiler R.¹

Institutes:¹Universitätsspital Bern, Universitätsklinik für Urologie, Bern, Switzerland, ²University of Bern, Dept. of Urology, Bern, Switzerland, ³University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ⁴University Hospital of Southampton, Dept. of Urology, Hampshire, United Kingdom, ⁵University of Bern, Institute of Pathology, Bern, Switzerland, ⁶Hiroshima University, Dept. of Urology, Hiroshima, Japan, ⁷GenomeDx, Biosciences, Vancouver, Canada

15:15 - 15:25

Molecular subtypes urothelial cancer

M. Sanchez-Carbayo, Vitoria-Gasteiz (ES)